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Healthcare policyAbstract Introduction: Data regarding real-world impact on cancer clinical research during
COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct
of paediatric cancer phase IeII trials in Europe through the experience of the Innovative Ther-
apies for Children with Cancer (ITCC).
Methods: A survey was sent to all ITCC-accredited early-phase clinical trial hospitals
including questions about impact on staff activities, recruitment, patient care, supply of inves-
tigational products and legal aspects, between 1st March and 30th April 2020.
Results: Thirty-one of 53 hospitals from 12 countries participated. Challenges reported
included staff constraints (30% drop), reduction in planned monitoring activity (67% drop
of site initiation visits and 64% of monitoring visits) and patient recruitment (61% drop
compared with that in 2019). The percentage of phase I, phase II trials and molecular plat-
forms closing to recruitment in at least one site was 48.5%, 61.3% and 64.3%, respectively.
In addition, 26% of sites had restrictions on performing trial assessments because of local con-
tingency plans. Almost half of the units suffered impact upon pending contracts. Most hospi-
tals (65%) are planning on improving organisational and structural changes.
Conclusion: The study reveals a profound disruption of paediatric cancer early-phase clinical
research due to the COVID-19 pandemic across Europe. Reported difficulties affected both
patient care and monitoring activity. Efforts should be made to reallocate resources to avoid
lost opportunities for patients and to allow the continued advancement of oncology research.
Identified adaptations to clinical trial procedures may be integrated to increase preparedness
of clinical research to futures crises.
ª 2020 Elsevier Ltd. All rights reserved.1. Introduction
The COVID-19 pandemic has led to a global healthcare
crisis, affecting more than 28 million individuals and
resulting in 917,417 deaths as of 14th September 2020
[1]. All European states, although not equally affected,
have been forced to make unprecedented adjustments to
prioritise resources against COVID-19 [2,3].Although clinical research is key to advancing medi-
cal knowledge and improving patient care, priority has
been given to COVID-19erelated patient care during
the pandemic. This has severely impacted essential
clinical research in other fields, such as cancer research
[4,5]. Coronavirus mitigation measures can affect the
conduct of clinical trials in many ways, e.g. patient
recruitment, completion of trial assessments, or
A. Rubio-San-Simón et al. / European Journal of Cancer 141 (2020) 82e9184provision of investigational medicinal products (IMPs)
[6]. Furthermore, pharmaceutical companies have
redirected their focus to developing diagnostics and
treatments against COVID-19, thus neglecting other
research areas [7].
To limit the downstream impact for patients and for
the drug industry, the European Medicines Agency [8]
and several national agencies [9e11] have issued guide-
lines on the management of clinical trial activities during
the pandemic. They are all aligned in the intention to
maintain trial activity, while assuring patient safety and
trial activities traceability, but no definitive recommen-
dations have been provided, making it difficult to create
a unified action plan. Across Europe, all parties (i.e.
healthcare authorities, regulators, sponsors) have
implemented different measures depending on the
impact of the pandemic in their countries and their ca-
pacity to adapt.
Particular attention should be given to patients in
cancer clinical trials because of their remarkable
vulnerability: cancer patients not only require timely
evaluation and treatment that does not allow for delays
[12], but also they may be vulnerable to COVID-
19erelated serious events [13,14]. The European Society
of Medical Oncology [15] and International Society of
Paediatric Oncology [16] have developed guidelines to
mitigate the deleterious effects of the pandemic on the
treatment of cancer patients. However, data regarding
real-world impact on cancer clinical research during
COVID-19 are scarce [17,18].
In this study, we evaluate the impact of the
COVID-19 pandemic on the early-phase clinical trial
activity in paediatric haematologyeoncology in
Europe. We analyse the experience of the Innovative
Therapies for Children with Cancer (ITCC) con-
sortium, an academic consortium dedicated to
improve the access to novel treatments for children
and adolescents with cancer in 13 European countries
[19,20].2. Methods
The local representatives from all 53 ITCC centres
accredited to conduct early-phase clinical trials in pae-
diatric cancer were contacted and sent a 93-item ques-
tionnaire. This questionnaire investigates the impact of
the pandemic on phase I/II clinical trials in solid and
haematological paediatric malignancies and molecular
screening cancer platforms (Appendix 1) between 1st
March and 30th April 2020. The online survey was
closed on 21st June. Descriptive statistics are provided
using SPSS Statistics (V.23 TM, Chicago). Additional
information about the status of the trials was obtained
from EudraCT (https://eudract.ema.europa.eu/) and the
National Library of Medicine clinical trial registry
(https://clinicaltrials.gov/).3. Results
Of the 53 ITCC sites, 31 (58.5%) responded, including
22 university hospitals, 6 cancer centres and 3 private
hospitals. All responses were complete and could be
included in the analysis. Participating sites accounted
for 12 European countries, with a fair representation
from Northern, Southern and Western Europe. Four-
teen sites were exclusively paediatric, while 17 treated
adults and children.
Sixty-four different phase I (n Z 33) and phase II
(n Z 31) trials and 14 different molecular platforms
were active and recruiting before 1st March. Phase I and
phase II trials and molecular platforms were open in a
median of four sites (interquartile range [IQR]: 1e7),
three sites (IQR: 1e9) and one site (IQR: 1e3.25),
respectively (Table 1).
3.1. Impact on clinical research staff
Of 31 units, 21 (68%) suffered shortages of on-site staff.
The median decrease in personnel across all professional
categories was 30% (IQR 0e48) per site. Main causes
were institutional contingency policies (58%), COVID-
19einfected workers (35%) and redeployment to other
hospital areas (7%).
Almost all units (28/31) managed to perform remote
data entry, although 23% (n Z 7) were not adequately
equipped for it and reported difficulties performing trial
activities from home-based offices.
3.2. Impact on on-site activities performed by sponsors
Most units experienced cancellations of site initiation
visits (SIVs) (65%) and monitoring visits (MVs) (87%).
Sixty-seven percent (n Z 35) of planned SIVs were
cancelled, while 29% (n Z 15) were performed remotely
and 4% (n Z 2) on-site. The decision to postpone visits
was taken by sponsors in half of the cases (49%), by
institutions (25%) and by sponsors and institutions
together (23%)
Sixty-four percent (n Z 196) of planned MVs were
cancelled, whereas 35% (n Z 109) were performed
remotely and 1% (n Z 4) on-site. The decision to post-
pone visits was predominantly taken jointly by sponsors
and institutions (45%) or by institutions alone (42%).
3.3. Impact on recruitment
The percentage of phase I and phase II trials and mo-
lecular platforms that closed to recruitment in at least
one site was 48.5% (n Z 16), 61.3% (n Z 19) and 64.3%
(n Z 9), respectively.
Eighty-one percent (n Z 25) of the units halted
recruitment of at least one trial or molecular platform
from their own portfolio. Five sites (16%) temporarily
interrupted recruitment for all active trials and
Table 1
Summary of responses to the survey provided by the 31 early-phase clinical trials units.
Items Total, n Total, %b
Baseline dataa Phase I trials active, recruiting 33
Phase II trials active, recruiting 31
Molecular platforms active, recruiting 14
Academic-sponsored trials and academic-sponsored molecular
platforms actively recruiting
38
Industry-sponsored trials actively recruiting 40
SIV previously scheduled for March/April 2020 52
MV previously scheduled for March/April 2020 309
Unit’s full-time workers 570
Total number of patients recruited in phase I/II studies in 2019 408
Total number of patients recruited in molecular platforms in 2019 495
Impact on personnel Number of units suffering any kind of shortages of on-site staff 21 68% (21/31)
Total reduction in number of on-site workers 170 30% (170/570)
Cause of on-site personnel shortage:
- COVID-19einfected workers
- Institutional contingency policy







Units performing remote data entry 28 90% (28/31)






Units suffering SIV cancellation 20 65% (20/31)
Number of SIV cancelled 35 67% (35/52)













Number of SIV performed remotely 15 29% (15/52)
Number of SIV performed on-site 2 4% (2/52)
Units suffering MV cancellation 27 87% (27/31)
Number of MV cancelled 196 64% (196/309)













Number of MV performed remotely 109 35% (109/309)
Number of MV performed on-site 4 1% (4/309)
Impact on recruitment Units that interrupted recruitment in all trials and molecular platforms 5 16% (5/31)
Units that interrupted recruitment in at least one trial 22 71% (22/31)
Units that interrupted recruitment in at least one molecular platformc 11 45% (11/24)
Trials with interrupted recruitment in at least one unit 35 55% (35/64)
Trials with interrupted recruitment in at least 50% of the units 17 26% (17/64)
Trials with interrupted recruitment in 100% of the units 9 14% (9/64)
Molecular platforms with interrupted recruitment in at least one unit 9 64% (9/14)
Molecular platforms with interrupted recruitment in at least 50% of
the units
7 50% (7/14)
Molecular platforms with interrupted recruitment in 100% of the units 5 36% (5/14)
New patients recruited to early-phase trials or to molecular platformsd 59
Impact on IMP and
research devices
Trials with IMP shortages 0 0%
Units shipping IMPs in at least one trial to the patient’s home or to the
local healthcare institution
18 58% (18/31)
Trials in which IMP were shipped to the patient’s home or to the local
healthcare centres
26
Units managing to increase IMP supply to patients 8 26% (8/31)
Units suffering shortages of research devices (e.g. sample kits) 3 10% (3/31)
Units that experienced difficulties to ship research samples 13 42% (13/31)
Impact on patient care
organisation
Units suffering any kind of limitations in patients’ care 15 48% (15/31)
Units conducting remote patient visits in other healthcare institutions
or by phone
24 77% (24/31)
Total number of patient visits conducted:





(continued on next page)
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Table 1 (continued )
Items Total, n Total, %b
- Patient visits conducted in other healthcare facilities




Patient visits rescheduled 48 6% (48/809)
Patient visits cancelled 8
Patients suffering treatment delays 10
Cause for patients suffering treatment delay:
- Not possible to ensure IMP supply
- Physician’s decision
- Patient/parents’ decision









Patients suffering treatment discontinuation 0
Units suffering restrictions to perform trial assessments 8 26% (8/31)
Potential patients not being able to be recruited into trials 23
Alternative provided to patients not being able to be recruited into
trials:






Impact on legal aspects Units suffering impact in pending contracts (e.g. contracts postponed,
or revision of budget delayed)
15 48% (15/31)
Pending contracts postponed 43
Units procured with sponsor contingency plans for the management of
issues related to the COVID-19
29 94% (29/31)
Units developing individual contingency plans for the management of
issues related to the COVID-19
29 94% (29/31)
ITCC countries whose National Regulatory Agency developed
contingency plans for the management of issues related to COVID-19
10 83% (10/12)










Unit Leads planning changes in organisation over the next months to
promote homeworking and remote MVs or SIVs
20 65% (20/31)
Unit Leads that believe that this crisis will make their units better
prepared for future crises
31 100% (31/31)
IMP: investigational medical product; ITCC: Innovative Therapies for Children with Cancer consortium.
MV: monitoring visit; SIV: site initiation visit; VPN: virtual private network.
a Baseline data refer to units’ status before 1st March. These are aggregated data from all units.
b Percentages may not always sum up to 100% due to rounding error.
c Among the 31 sites, 77% (n Z 24) had molecular platforms.
d Defined by having started trial treatment or having had their tumour profiled.
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the other 26 sites, the proportion of industry-sponsored
trials and molecular platforms that halted recruitment
was 18% against the 9% of academic trials/platforms.
Fifty-nine new patients were enrolled across all units
in this period, 61% less than the bimonthly 2019 average
(n Z 150).
The impact on clinical trial activities, as measured by
the rate of studies that were put on hold during that
period (Fig. 1), or the relative change in the number of
recruited patients compared with that in 2019 (Fig. 2),
was heterogeneous across countries.
3.4. Impact on organisation of patient care
All units continued to perform on-site patient visits, but
48% (n Z 15) reported limitations in providing best care
for patients. Eight units (26%), seven of which were
located in mixed adultepaediatric centres, hadrestrictions on performing trial assessments due to local
strategies (e.g. procedures requiring anaesthesia because
of shortage of specialists, fewer slots due to prolonged
inter-patient intervals or cancellation of out-patient
visits in other disciplines).
Of 809 patient visits performed, 80% were conducted
on-site (n Z 646), while 13% (n Z 104) were conducted
by phone and 7% (n Z 59) in local hospitals closer to
families’ home. Only eight patient visits were definitively
cancelled.
Among patients being actively treated, 10 experi-
enced treatment delays because of COVID-19erelated
concerns: physician’s decision to guarantee patient’s
safety (n Z 8), hospital organisational policy (n Z 1)
and parents’ fear of COVID-19 (n Z 1). No patient on
the trial had study discontinuation due to COVID-19.
Twenty-three potentially eligible patients could not
be screened for trials becuse of COVID-19erelated























Fig. 1. OverviewofCOVID-19 diffusion and studies interruption in ITCCcountries during the time of the present survey. The percentage of
trials and molecular platforms whose recruitment was interrupted per country during the period between 1st of March and 30th April 2020.
COVID-19 confirmed infected cases per countries during the periodbetween 1st ofMarch and 30thApril 2020.Based on data from theWorld












Fig. 2. Relative change in recruitment per country during the period between 1st of March and 30th April 2020 compared with that the
2019 bimonthly mean.
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did not receive anticancer treatment at that time point.
3.5. Impact on supply of investigational medicinal
products and research devices
Provision of IMPs was uniformly maintained at all times.
Only three units (10%) suffered research devices shortage
(e.g. sample kits). Forty-two percent (n Z 13) of sites
experienced difficulties shipping research samples.
Eighteen units could ship IMPs to patients’ homes or
local hospitals. In all these cases, the sponsor supportedthe shipment of the IMPs. For 16 trials, eight units
managed to provide larger amounts of trial medications
to patients to minimise hospital visits.
3.6. Impact on administrative and regulatory aspects
Almost half of the units (48%, n Z 15) suffered impact
on administrative and regulatory aspects (e.g. delays in
ethics committee submissions, review of trials budget),
and the completion of 43 contracts was delayed.
In nearly all units (94%, nZ 29), local protocols were
created, and sponsors procured contingency plans for
A. Rubio-San-Simón et al. / European Journal of Cancer 141 (2020) 82e9188the management of COVID-19 issues. National regula-
tory authorities from 10 of 12 countries surveyed (83%)
and developed specific guidance for the conduct of
clinical trials during the COVID-19 emergency.
3.7. Future perspective
Sixty-five percent of sites foresee a similar recruitment in
2020 compared with 2019, whereas 35% lower. Most
units (65%) are implementing changes to promote
remote working and SIVs/MVs.
Fifty-eight percent (n Z 18) of interviewees respon-
ded to the open question about COVID-19erelated
considerations. Homogenously, they pointed out the
proactive attitude from the site staff to develop strate-
gies to minimise potential risks to patient safety and to
assure compliance with trial procedures. All in-
vestigators agreed that this episode will make units
better prepared for future crises.
4. Discussion
This study reveals a profound disruption of paediatric
cancer early clinical research due to the COVID-19
pandemic across Europe. Healthcare adjustments were
made initially assuming that the pandemic would be
brief, but we have come to realise that the pandemic
and its consequences are unlikely to dissipate soon.
Because children with cancer have an unmet need to
access innovative therapies [21], now is the right time to
think how to fulfil their needs in this ‘new normal’
setting.
With hospitals diverting resources to care for
COVID-19 patients, personnel shortages were a major
concern in most units. Physicians and nurses’ activities
are patient-centred and therefore more susceptible to be
compromised by COVID-19 mitigation measures.
Nevertheless, the efforts of healthcare workers to
address the issues resulting from this crisis enabled
continued care provision for most patients. Other pro-
fessionals, such as study coordinators or data managers,
may continue to perform home-based work more easily.
In this regard, most units managed remote data entry,
although 23% of them reported to not having the
appropriate means to do so. Efforts should be made to
implement homeworking solutions under the perspective
of COVID-related restrictions expected throughout up-
coming months. Although reallocation of staff to other
areas to fight against COVID-19 is logical in this
context, it has an undeniable impact on areas with
highly specialised and multidisciplinary activities, such
as clinical research.
Our study shows drastic suspension of SIVs and
MVs. The decisions leading to delaying SIVs are un-
derstandable because of the inherent complexity of
early-phase studies. However, SIVs should berescheduled as soon as possible to avoid lost opportu-
nities for patients with no other therapeutic options. In
our study, 15 SIVs were performed remotely, demon-
strating the feasibility of this procedure. Regarding
MVs, only 36% were performed. MVs ensure trial safety
and data quality; their suspension may lead to unknown
consequences upon the integrity of trials. Hence, it is
necessary that sponsors implement alternative mecha-
nisms to resume MVs in collaboration with research
teams via reinforced remote communication. Potential
impacts of weakening monitoring could be magnified by
protocol deviations or delayed visits. Although sponsors
provided guidelines to record deviations related to
COVID-19 [22,23], regulators should take a sensible
approach when reviewing these deviations, especially as
most would not compromise patient safety.
More than 50% of the trials and 60% of the molecular
platforms interrupted recruitment in at least one unit,
and 80% of the sites halted recruitment of at least one
trial or molecular platform. The proportion of industry
trials stopped is twice the proportion of academic trials,
highlighting the key role that academic researchers plays
in times of crises and their commitment to cancer patient
health over other considerations. Furthermore, patient
recruitment during these two months was severely
impacted with a 61% drop compared with that in 2019.
The reasons for this drop cannot be explained by the
halt in trial recruitment alone, but also by individual
national lockdown strategies and institutional contin-
gency policies, among others. All efforts should be made
to resume recruitment as soon as possible, particularly
for phase II trials or molecularly driven studies that
have higher chances of success [24].
In an attempt to minimise patient risk, 77% of sites
performed remote patient visits in other healthcare in-
stitutions or by phone. Although the general population
was advised not to visit hospitals because of infection
risk, this could constitute a major problem for patients
receiving investigational treatments if adverse events do
not receive the necessary medical attention or if they
suffer treatments delays. Cortiula et al. [12] highlighted
the negative implications of excessive focus on COVID-
19 and of overshadowing other aspects of clinical
practice, especially in cancer care.
Fortunately, according to our data, no patient dis-
continued treatment because of COVID-19. Nevertheless,
23 potentially eligible patients could not be recruited
because of COVID-19erelated issues. It should be
pointed out that whereas COVID-19 has a low mortality
rate in children [25], more than 90% of children with
relapsed cancers will continue to die. Therefore, consid-
ering the safety profile and oral nature of the treatment for
most novel anticancer agents, a riskebenefit assessment
should be conducted, and cancer treatment continuation
should be promoted. Moreover, the stalling process on
experimental medicines may extend the already lengthy
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take longer to reach the patients across the globe [26].
Several stakeholders are advocating seizing the op-
portunity to keep the positive clinical trial adaptations
implemented during this pandemic permanently
[27e29]. Doherty et al. [27] recently suggested changes
in trial design and trial implementation so that research
units can better cope with future crisis. They include
generalisation of virtual visits leaving face-to-face visits
for patients and trial monitors only if necessary,
administration of medication at home, and efficacy as-
sessments performed closer to patient’s home. These
suggestions are already in line with some of those raised
by the ITCC investigators, and we agree that this is the
right time to invest in structural and regulatory changes,
so that clinical research is not compromised again to the
extent we have seen in this crisis.
Although there are multiple publications about the
impact of generic emergency situations in health settings
[30,31], there is minimal information that focuses spe-
cifically on repercussions on paediatric clinical trials
sites [17,18]. The American Society of Clinical Oncology
recently published an analysis of the impact of COVID-
19 on the conduct of oncology clinical trials [17].
Although focused on the United States research pro-
grams in adults, it reports numerous challenges with
conducting clinical trials that we have also observed,
including enrolment and protocol adherence difficulties
or staff constraints.
We acknowledge some limitations of this study. First,
its retrospective nature may have limited the accuracy of
the data reported, magnified by the fact that during that
period site staff were working under unprecedented
pressure. Second, some countries were only represented
by a fraction of their ITCC sites, therefore potentially
limiting the interpretation of individual countries
impact. On the other hand, the site coverage, measured
by the response rate from the sites, was high (58.5%); 12
of the 14 countries that are part of ITCC were repre-
sented, and all sites provided substantially complete
responses valid for the analysis; this strengthens the
reproducibility and generalisation of the results.
With this study we have identified an extensive disrup-
tion in paediatric cancer research during COVID-19 crisis
across Europe.We also provided insight into the efforts of
sponsors and research teams to maintain access to exper-
imental therapies despite the difficulties. Disruption of
ongoing trials wastes time and resources, may reduce pa-
tient access to active treatment and carry long-termknock-
on effects on drug development. To mitigate the impact,
knowledge provided in this study may help reach a
consensus strategy for enhancing the adaptability of pae-
diatric clinical trials sites to future crises.Authors’ contributions
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